Real-time trade and investing ideas on Progenics Pharmaceuticals Inc. PGNX from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. $PGNX Stock Technical Analysis | Progenics | SwingTradeBot.com Sep 27, 2019 · PGNX closed down 9.74 percent on Wednesday, April 1, 2020, on 72 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected. PGNX: Progenics Pharmaceuticals Inc. - 12 Month EPS ... Zacks Investment Research is releasing its prediction for PGNX based on the 1-3 month trading system that nearly triples the S&P 500. the PGNX analysis is free » The Price and 12 Month Progenics Pharmaceuticals, Inc. - PGNX Stock Chart ...
Mar 10, 2020 · Progenics Pharmaceuticals (PGNX) stock traded 872309 shares in most recent trading session as compared to an average volume of 910.10K shares. It shows that the shares were traded in the recent trading session and traders shown interest in PGNX stock. Shares of the Progenics Pharmaceuticals (PGNX) lost -11.48% to trade at $4.01 on Monday trading session.
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate PGNX Stock Price Quote & News - Progenics Pharmaceuticals ... View the real-time PGNX price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Progenics Pharmaceuticals against related stocks people have also bought like GERN, VKTX, VSTM, and TEVA. 2,069 people own Progenics Pharmaceuticals on Robinhood on April 4, 2020. Here's Why Shares of Progenics Pharmaceuticals Inc. Sank ... Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) are down 16.8% at 12:07 p.m. EDT after releasing disappointing top-line data for the phase 3 clinical trial testing its prostate cancer imaging NASDAQ:PGNX Progenics Pharmaceuticals, Inc. Stock Analysis ... Progenics Pharmaceuticals, Inc. engages in developing medicines for oncology. It offers clinical trials of product candidates for prostate cancer, and resumed a pivotal trial of an ultra-orphan radiotherapy candidate for pheochromocytoma.
PGNX | Progenics Pharmaceuticals Inc. Stock Price & News - WSJ
Apr 01, 2020 · Stock quote and company snapshot for PROGENICS PHARMACEUTICALS INC (PGNX), including profile, stock chart, recent news and events, analyst opinions, and research reports.
Progenics Pharmaceuticals (PGNX) reports earnings on 6/12/2020. Shares are up 5.5% since reporting last quarter. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings.
PGNX | Complete Progenics Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Progenics Pharmaceuticals Inc. (PGNX) Stock Price, Quote ...
Progenics Pharmaceuticals Inc. (PGNX) Analyst Ratings ...
Progenics Pharmaceut. PGNX. Real-time BATS EXCHANGE - 03/16 04:00:00 pm . 2.29USD. -27.30% 17 Mar 2020 On Monday, shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) marked $2.22 per share versus a previous $3.15 closing price. Should you invest in Progenics Pharmaceuticals (NasdaqGS:PGNX)? Highly volatile share price over past 3 months Debt to Equity History and Analysis Learn about PGNX with our data and independent analysis including price, star rating, valuation, dividends, and Stocks by Morningstar Classification Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings,
Nov 05, 2019 · Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 300.00%. The high price target for PGNX is $14.00 and the low price target for PGNX is $10.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy." Progenics Pharmaceuticals (NasdaqGS:PGNX) - Share price ... It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York. Show less